Human Longevity Inc.

Human Longevity Inc.

Human genome sequencing company founded in 2013 and based in San Diego, CA. Human Longevity Inc. is building a database with genomic and phenotypic information and aims to make medicine more data-driven by combining DNA sequencing, expert analysis and machine learning

Human Longevity Inc. is a biotechnology company using biological data to create medicine that is headquartered in San Diego, California and was founded in 2013 by Craig Venter, Peter Diamandis, and Robert Hariri.

Human Longevity is developing a database on human genotypes and phenotypes to develop diagnostics and therapeutics against aging-related human diseases and conditions. Human Longevity Inc. databases are available to pharmaceutical, biotechnology and academic organizations.

They are developing cell-based therapeutics to address decline in endogenous stem cell function and also focus on cancer, diabetes, obesity, heart and liver diseases and dementia. The company performs sequencing and provides human genome sequencing and offers genomic analysis with predictive and preventative care, as well as cancer analysis, newborn screening and screening for rare and undiagnosed diseases. Human Longevity also provides personalized vaccines and cell therapies.

One of the co-founders of Human Longevity is J. Craig Venter which played a large role in the Human Genome Project. Venter left the company in May 2018 and has been accused of misappropriation of trade secrets in a Human Longevity lawsuit filed against him. Venter emailed a statement to Quartz stating that the claims are without merit and that the J. Craig Venter Institute will defend against the allegations and also that Venter is still a shareholder at Human Longevity Inc.

Funding

Series A

On March 4, 2014 Human Longevity completed their series A funding round with $80 million in funding from Synthetic Genomics, OS Fund, Illumina Ventures, DFJ, Celgene, Tan Thay, and Daniel Curran.

Series B

On April 5, 2016 Human Longevity completed their series B funding round with $220 million in funding from Illimina Ventures (lead investor), OS Fund, StartUp Health, GE Ventures, DFJ, Celgene, and Amino Capital.

Timeline

2013

Human Longevity Inc. was founded by Peter Diamandis, Robert Hariri and J. Venter.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

DAVID S. KAROW

Chief of Radiogenomics & Interim Chief Executive Officer

PAMILA BRAR

Chief Medical Officer

Peter H. Diamandis

Co-Founder

Robert (Bob) Hariri

Co-Founder, President Human Longevity Cellular Therapeutics

SCOTT SORENSEN

Chief Technology Officer

TRAVIS LACEY

Chief Corporate Development Officer

Further reading

Title
Author
Link
Type
Date

Former unicorn genetics startup Human Longevity loses its horn

KEVIN TRUONG

Web

Documentaries, videos and podcasts

Title
Date
Link

Introducing Human Longevity, Inc. Health Nucleus

October 27, 2015

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.